Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study
机构：[1]Chinese People's Liberation Army Cancer Center of Nanjing Bayi Hospital, Nanjing, China[2]Shanghai East Hospital, Shanghai, China[3]Department of Medical Oncology, Zhejiang Cancer Hospital, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China浙江省肿瘤医院[4]Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, China[5]Taizhou First People's Hospital, Taizhou, China[6]Tongji Medical College, Huazhong University of Science and Technology, Hubei, China[7]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[8]The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China[9]The Third Xiangya Hospital of Central South University, Changsha, China[10]Zhongshan City People's Hospital, Zhongshan, China[11]Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China临床科室肿瘤内科河北医科大学第四医院[12]The First Affiliated Hospital of Chongqing Medical University, Chongqing, China重庆医科大学附属第一医院[13]The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai, China[14]The First Affiliated Hospital/School of Clinical Medicine Guangdong Pharmaceutical University, Guangzhou, China[15]The First People's Hospital of Foshan, Foshan, China[16]Shanghai Henlius Biotech, Inc., Shanghai, China
第一作者机构：[1]Chinese People's Liberation Army Cancer Center of Nanjing Bayi Hospital, Nanjing, China[2]Shanghai East Hospital, Shanghai, China[3]Department of Medical Oncology, Zhejiang Cancer Hospital, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China[4]Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, China[5]Taizhou First People's Hospital, Taizhou, China[6]Tongji Medical College, Huazhong University of Science and Technology, Hubei, China[7]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[8]The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China[9]The Third Xiangya Hospital of Central South University, Changsha, China[10]Zhongshan City People's Hospital, Zhongshan, China[12]The First Affiliated Hospital of Chongqing Medical University, Chongqing, China[13]The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai, China[14]The First Affiliated Hospital/School of Clinical Medicine Guangdong Pharmaceutical University, Guangzhou, China[15]The First People's Hospital of Foshan, Foshan, China[16]Shanghai Henlius Biotech, Inc., Shanghai, China
推荐引用方式(GB/T 7714)：
Qin Shukui,Li Jin,Zhong Haijun,et al.Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study[J].JOURNAL OF CLINICAL ONCOLOGY.2021,39(15):doi:10.1200/JCO.2021.39.15_suppl.2566.
APA：
Qin, Shukui,Li, Jin,Zhong, Haijun,Jin, Chuan,Chen, Lili...&Wang, Qingyu.(2021).Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.JOURNAL OF CLINICAL ONCOLOGY,39,(15)
MLA：
Qin, Shukui,et al."Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study".JOURNAL OF CLINICAL ONCOLOGY 39..15(2021)
医学